FINWIRES · TerminalLIVE
FINWIRES

財報季和德黑蘭提案提振亞洲股市

By

-- 週一,亞洲股市普遍上漲,科技股走強以及媒體報導德黑蘭已提出重新開放霍爾木茲海峽的提議提振了市場情緒。北京方面公佈的整體良好的工業企業獲利報告也提振了市場情緒。 上海和東京股市收漲,香港股市小幅下跌。其他地區性交易所多收高。 在日本,日經225指數開盤走勢平穩,但最終收漲1.4%,創下歷史新高。強勁的獲利報告抵消了避險情緒的影響。 日經225指數上漲821.18點,收在60,537.36點,首次突破60,000點大關。儘管下跌個股數量超過上漲個股,比例為129比94。 工業機器人製造商發那科(Fanuc)領漲,漲幅達16%,而中外製藥(Chugai Pharmaceutical)下跌15.8%,兩家公司的股價波動均源自財報發布。 香港恆生指數收跌0.2%,受房地產股拖累。 恆生指數下跌52.42點,收25,925.65點,下跌個股數量超過上漲個股,比例為53比36。恆生科技指數當日上漲0.8%,而內地房地產指數下跌0.7%。 中芯國際領漲,漲幅達6.1%,國藥集團下跌3.8%。 內地方面,上證綜指上漲0.2%,收在4,086.34點。 經濟新聞方面,國家統計局數據顯示,3月份中國工業企業獲利年增15.8%,主要得益於民營企業的強勁成長。該機構的調查對象為年營業額超過290萬美元的企業。 其他地區交易所方面,韓國綜合股價指數上漲2.2%。台灣加權指數(TWSE)上漲1.8%;澳洲ASX 200指數下跌0.2%;新加坡海峽時報指數下跌0.6%;泰國SET指數上漲1.6%。孟買Sensex指數在尾盤交易中上漲0.8%。 MSCI亞太地區所有國家指數當日上漲1.2%。

Related Articles

Treasury

Scotiabank Previews This Week's February and Preliminary March GDP for Canada

Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.

$$CXY
Australia

Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing

Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%

$VICR
Australia

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%

$BMRN$FOLD